{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:01:58Z","timestamp":1789592518396,"version":"build-2803163510"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1053\/j.semnuclmed.2017.09.002","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T17:18:01Z","timestamp":1508001481000},"page":"17-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Interim FDG-PET Imaging in Lymphoma"],"prefix":"10.1053","volume":"48","author":[{"given":"Andrea","family":"Gallamini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Zwarthoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0015","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.2967\/jnumed.108.057174","article-title":"Assessing tumor response to therapy","volume":"50","author":"Weber","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0025","first-page":"1521","article-title":"Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose","volume":"29","author":"Minn","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0030","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1993.11.11.2101","article-title":"Metabolic monitoring of breast cancer chemo-hormonotherapy using positron emission tomography: Initial evaluation","volume":"11","author":"Wahl","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0040","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2013.53.2838","article-title":"In vivo treatment sensitivity testing with positron emission tomography\/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma","volume":"32","author":"Hutchings","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0045","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18]Fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0050","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0055","series-title":"Uber den Stoffwechsel der Tumoren: Arbeiten aus dem Kaiser Wilhelm-Institut f\u00fcr Biologie. Berlin-Dahlem","author":"Warburg","year":"1926"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13550-016-0220-9","article-title":"The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) as a pathway-specific biomarker with AZD8186, a PI3K\u03b2\/\u03b4 inhibitor","volume":"6","author":"Maynard","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0065","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s00259-016-3425-2","article-title":"Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery","volume":"43","author":"Lopci","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0070","doi-asserted-by":"crossref","first-page":"217111","DOI":"10.3109\/10428194.2010.529208","article-title":"Report on the Second International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 8-9 April 2010","volume":"51","author":"Meignan","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0075","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3109\/10428190903308056","article-title":"Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: Qualitative or quantitative Interpretation\u2014where do we stand?","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0080","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2967\/jnumed.107.039867","article-title":"18F-FDG-PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: A systematic review","volume":"49","author":"Terasawa","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.semnuclmed.2012.02.003","article-title":"Use of dual point fluorodeoxyglucose imaging to enhance sensitivity and specificity","volume":"42","author":"Schillaci","year":"2012","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0095","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0100","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/annonc\/mdl122","article-title":"Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin disease patients","volume":"17","author":"Zinzani","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0105","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"Lin","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0110","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report of the First International Workshop on Interim PET Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0115","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphoma Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0120","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3109\/10428194.2012.735667","article-title":"Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy","volume":"54","author":"Filippi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0135","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/annonc\/mdn768","article-title":"FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value","volume":"20","author":"Markova","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","article-title":"Early interim 18 F-FDG PET in Hodgkin's lymphoma: Evaluation on 304 patients","volume":"39","author":"Zinzani","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0145","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0150","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2010-10-314260","article-title":"Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I\/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET","volume":"117","author":"Straus","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0155","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/cncr.22276","article-title":"FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease","volume":"107","author":"Kostakoglu","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0160","first-page":"475","article-title":"The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease","volume":"91","author":"Gallamini","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0165","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2007-09-112128","article-title":"Proteomics analysis of Hodgkin lymphoma: Identification of new players involved in the cross-talk between HRS and infiltrating lymphocytes","volume":"111","author":"Ma","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0170","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin lymphoma: Increasing evidence of the importance of microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0175","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/blood-2012-03-403790","article-title":"Interim FDG-PET in Hodgkin lymphoma: A compass for a safe navigation in clinical trials?","volume":"120","author":"Gallamini","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0180","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD 15 trial): A randomized, open-label, phase 3, non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0185","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0190","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1182\/blood-2014-05-577627","article-title":"The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early stage disease","volume":"124","author":"Evens","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0195","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early stage Hodgkin's lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0200","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited stage Hodgkin's lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0210","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced intensity treatment in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0215","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavourable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD 11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000318885","article-title":"Meta-analyses of early stage Hodgkin's lymphoma","volume":"125","author":"Herbst","year":"2011","journal-title":"Acta Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0225","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity chemotherapy in patients with relapsed Hodgkin's lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0230","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective treatment as induction chemotherapy before autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: Final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0235","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Brockelmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0240","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00259-009-1258-y","article-title":"Unifying the predictive value of pretransplant FDG-PET in patients with lymphoma: A review and meta-analysis of published trials","volume":"37","author":"Poulou","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0245","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab-vedotin followed by augmented ifosfamide, carboplatinum and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single center, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0250","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.110.080556","article-title":"Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: Importance of the reference background","volume":"51","author":"Itti","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0260","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2009-08-234351","article-title":"Interim positron emission tomography scans in diffusa large B-cell lymphoma. An independent expert nuclear medicine evaluation of the Eistern Cooperative Oncology Group E3404 study","volume":"115","author":"Horning","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0265","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0270","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","article-title":"Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab","volume":"30","author":"Safar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0275","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: Comparison between Deauville criteria and DeltaSUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0280","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2967\/jnumed.114.145326","article-title":"Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma","volume":"55","author":"Carr","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0285","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0290","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0295","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.seminhematol.2015.01.004","article-title":"Current status of the role of PET imaging in diffuse large B-cell Lymphoma","volume":"52","author":"Moskowitz","year":"2015","journal-title":"Semin Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0305","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CCO.0b013e3282f5123d","article-title":"FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma","volume":"20","author":"Kasamon","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0310","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2016-05-672196","article-title":"Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver?","volume":"129","author":"Le Gouill","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0315","first-page":"603","article-title":"Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy","volume":"47","author":"Engles","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0320","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00259-003-1120-6","article-title":"[18F]FDG PET monitoring of tumor response to chemotherapy: Does [18F]FDG uptake correlate with the viable tumor cell fraction ?","volume":"30","author":"Spaepen","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0325","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0330","article-title":"Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores","author":"Kim","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0335","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s00259-015-3002-0","article-title":"Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE-EORTC 62072\/VEG110727: A randomized, double-blind, placebo-controlled phase III trial","volume":"42","author":"Hristova","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0340","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathological findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0345","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem cell transplantation in peripheral T-cell lymphoma. NLG-TG-01","volume":"30","author":"D'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0350","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET scan in peripheral T-cell lymphomas: A review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0355","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.116.180406","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma","author":"Cottereau","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0360","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1038\/bcj.2016.2","article-title":"The prognostic value of interim and end-of-treatment PET\/CT in patients with newly diagnosed Peripheral T-cell lymphoma","volume":"6","author":"Ham","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0365","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F] Fluorodeoxyglucose positron emission tomography predicts survival after chemo-immunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0370","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2016.02.057","article-title":"Prognostic role of pre-radiation therapy 18F-fluorodeoxyglucose positron emission tomography for primary mediastinal B-cell lymphomas treated with R-CHOP or R-CHOP-like chemotherapy plus radiation","volume":"95","author":"Filippi","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0375","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/RLU.0000000000000892","article-title":"The Deauville 5-point scale improves the prognostic value of interim FDG-PET\/CT in extranodal natural Killer\/T cell lymphoma","volume":"40","author":"Jiang","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0380","doi-asserted-by":"crossref","first-page":"41057","DOI":"10.1038\/srep41057","article-title":"Utility of baseline, interim and end-of-treatment 18F-FDG PET\/CT in extranodal natural killer\/T cell lymphoma patients treated with L-asparaginase\/pegaspargase","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0385","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V126.23.578.578","article-title":"Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy\/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB\/alliance 50604)","volume":"126","author":"Straus","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0390","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0395","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer. H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0400","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment of stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0405","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0415","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0420","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response adapted for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose\u2013positron emission tomography imaging: Southwest Oncology Group S 0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1053\/j.semnuclmed.2017.09.002_bib0425","first-page":"163","article-title":"Interim PET-adapted chemotherapy in advanced Hodgkin lymphoma (HL). Results of the second interim analysis of the Italian GITIL\/FIL HD 0607 trial","volume":"33","author":"Gallamini","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0430","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","article-title":"Randomized phase III trial comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin Lymphoma: Interim analysis of the AHL2011 Lysa Study","volume":"126","author":"Casasnovas","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0435","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood.V128.22.1857.1857","article-title":"Positron emission tomography (PET) guided therapy of aggressive lymphomas\u2014interim PET-based outcome prediction and treatment changes in patients with B cell lymphomas participating in the PETAL trial","volume":"128","author":"Duhrsen","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0440","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90-Y ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0445","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0450","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0455","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2017.09.002_bib0460","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0465","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2339","article-title":"Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: Interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study","author":"Ceriani","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0470","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00259-014-2715-9","article-title":"qPET\u2014a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma","volume":"41","author":"Hasenclever","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0475","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.14728","article-title":"Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET\/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study","volume":"178","author":"Ceriani","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2017.09.002_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2016.1277384","article-title":"Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma","volume":"58","author":"Fan","year":"2017","journal-title":"Leuk Lymphoma"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129981730079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129981730079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T22:34:33Z","timestamp":1603146873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000129981730079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S000129981730079X"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.002","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim FDG-PET Imaging in Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}